NO20090266L - Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer - Google Patents

Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer

Info

Publication number: NO20090266L
Authority: NO; Norway
Prior art keywords: treatment; mediated diseases; derivatives useful; gpr38 receptor; piperazinyl derivatives
Prior art date: 2006-06-28

Application number

NO20090266A

Other languages

English (en)

Norwegian (no)

Inventor

Mervyn Thompson

Susan Marie Westaway

Darren Jason Mitchell

Jonathan Thomas Seal

Samantha Louisa Brown

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-28

Filing date

2009-01-16

Publication date

2009-03-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38476358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090266(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-06-28 Priority claimed from GB0612844A external-priority patent/GB0612844D0/en

2007-06-14 Priority claimed from GB0711525A external-priority patent/GB0711525D0/en

2009-01-16 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2009-03-17 Publication of NO20090266L publication Critical patent/NO20090266L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Diabetes (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Nutrition Science (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

NO20090266A 2006-06-28 2009-01-16 Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer NO20090266L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0612844A GB0612844D0 (en)	2006-06-28	2006-06-28	Compounds
GB0711525A GB0711525D0 (en)	2007-06-14	2007-06-14	Compounds
PCT/EP2007/056342 WO2008000729A1 (fr)	2006-06-28	2007-06-26	Dérivés de pipérazinyle utiles dans le traitement de maladies induites par le récepteur gpr38

Publications (1)

Publication Number	Publication Date
NO20090266L true NO20090266L (no)	2009-03-17

Family

ID=38476358

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20090266A NO20090266L (no)	2006-06-28	2009-01-16	Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer

Country Status (29)

Country	Link
US (2)	US7700599B2 (fr)
EP (1)	EP2041093B1 (fr)
JP (1)	JP5028484B2 (fr)
KR (1)	KR20090031688A (fr)
AR (1)	AR061656A1 (fr)
AT (1)	ATE465150T1 (fr)
AU (1)	AU2007263712B2 (fr)
BR (1)	BRPI0713443A2 (fr)
CA (1)	CA2655540A1 (fr)
CR (1)	CR10497A (fr)
CY (1)	CY1110190T1 (fr)
DE (1)	DE602007006019D1 (fr)
DK (1)	DK2041093T3 (fr)
EA (1)	EA015820B1 (fr)
ES (1)	ES2344484T3 (fr)
HR (1)	HRP20100284T1 (fr)
IL (1)	IL195900A0 (fr)
JO (1)	JO2645B1 (fr)
MA (1)	MA30539B1 (fr)
MX (1)	MX2009000110A (fr)
MY (1)	MY147677A (fr)
NO (1)	NO20090266L (fr)
NZ (1)	NZ573450A (fr)
PE (1)	PE20080345A1 (fr)
PL (1)	PL2041093T3 (fr)
PT (1)	PT2041093E (fr)
SI (1)	SI2041093T1 (fr)
TW (1)	TWI391386B (fr)
WO (1)	WO2008000729A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0611907D0 (en)	2006-06-15	2006-07-26	Glaxo Group Ltd	Compounds
PE20070180A1 (es) *	2005-07-26	2007-04-25	Glaxo Group Ltd	Compuestos de bencilpiperazina como agonistas del receptor gpr38
GB0524814D0 (en) *	2005-12-05	2006-01-11	Glaxo Group Ltd	Compounds
AU2007263712B2 (en) *	2006-06-28	2012-08-30	Glaxo Group Limited	Piperazinyl derivatives useful in the treatment of GPR38 receptor mediated diseases
GB0723317D0 (en) *	2007-11-28	2008-01-09	Glaxo Group Ltd	Compounds
JP5663743B2 (ja) *	2009-02-27	2015-02-04	ラクオリア創薬株式会社	モチリン受容体作動活性を有するオキシインドール誘導体
US9452980B2 (en) *	2009-12-22	2016-09-27	Hoffmann-La Roche Inc.	Substituted benzamides
WO2011092293A2 (fr)	2010-02-01	2011-08-04	Novartis Ag	Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
AR080055A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
CN102753527B (zh)	2010-02-02	2014-12-24	诺华股份有限公司	用作crf受体拮抗剂的环己基酰胺衍生物
BR112013007145A2 (pt)	2010-09-27	2016-06-14	Daiichi Sankyo Co Ltd	composto ou sal farmacologicamente aceitável, medicamento, e, uso do composto ou sal farmacologicamente aceitável
US9321727B2 (en) *	2011-06-10	2016-04-26	Hoffmann-La Roche Inc.	Pyridine derivatives as agonists of the CB2 receptor
RU2731095C2 (ru)	2016-03-17	2020-08-28	Ф. Хоффманн-Ля Рош Аг	Производное 5-этил-4-метил-пиразол-3-карбоксамида, обладающее активностью агониста taar
CA3193204A1 (fr) *	2020-09-25	2022-03-31	Shanghai Meiyue Biotech Development Co., Ltd.	Compose pyrimidine carboxamide et son application

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5385912A (en) *	1991-03-08	1995-01-31	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
TW355711B (en)	1992-11-04	1999-04-11	Chugai Pharmaceutical Co Ltd	Erythromycin derivatives
JPH06211886A (ja)	1992-11-04	1994-08-02	Chugai Pharmaceut Co Ltd	エリスロマイシン誘導体
US5593994A (en) *	1994-09-29	1997-01-14	The Dupont Merck Pharmaceutical Company	Prostaglandin synthase inhibitors
JP3901239B2 (ja)	1996-03-13	2007-04-04	大正製薬株式会社	アリールアルカン誘導体
US5965578A (en) *	1996-04-03	1999-10-12	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
DE19644195A1 (de)	1996-10-24	1998-04-30	Solvay Pharm Gmbh	10,13,15-Trioxatricyclo[9.2.1.1.·9·.·6·]-pentadecanon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6100239A (en) *	1996-11-26	2000-08-08	Chugai Seiyaku Kabushiki Kaisha	13-membered ring macrolide compound, medicine containing the same, and process for producing the same
US6060491A (en) *	1997-06-19	2000-05-09	Dupont Pharmaceuticals	6-membered aromatics as factor Xa inhibitors
US5972939A (en) *	1997-10-28	1999-10-26	Ortho-Mcneil Pharmaceutical, Inc.	Cyclopentene derivatives useful as antagonists of the motilin receptor
US6165985A (en)	1998-02-13	2000-12-26	Solvay Pharmaceuticals Gmbh	11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
DE19805822B4 (de)	1998-02-13	2009-02-05	Solvay Pharmaceuticals Gmbh	11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9804734D0 (en) *	1998-03-05	1998-04-29	Pfizer Ltd	Compounds
CN101481359A (zh) *	1999-04-15	2009-07-15	布里斯托尔-迈尔斯斯奎布公司	环状蛋白酪氨酸激酶抑制剂
US20020052380A1 (en) *	2000-02-18	2002-05-02	Dinsmore Christopher J.	Inhibitors of prenyl-protein transferase
US20020010184A1 (en) *	2000-02-18	2002-01-24	Dinsmore Christopher J.	Inhibitors of prenyl-protein transferase
WO2001068621A1 (fr) *	2000-03-13	2001-09-20	Ortho-Mcneil Pharmaceutical, Inc.	Derives de cyclohexene utiles comme antagonistes du recepteur de la motiline
US6384031B2 (en) *	2000-03-13	2002-05-07	Ortho-Mcneil Pharmaceutical, Inc.	Cyclobutene derivatives useful as antagonists of the motilin receptor
WO2001068620A1 (fr) *	2000-03-13	2001-09-20	Ortho-Mcneil Pharmaceutical, Inc.	Nouveaux derives cyclopentene utiles comme antagonistes du recepteur de la motiline
US6511980B2 (en) *	2000-05-05	2003-01-28	Ortho Mcneil Pharmaceutical, Inc.	Substituted diamine derivatives useful as motilin antagonists
GB0013378D0 (en) *	2000-06-01	2000-07-26	Glaxo Group Ltd	Use of therapeutic benzamide derivatives
US7102009B2 (en) *	2001-01-12	2006-09-05	Amgen Inc.	Substituted amine derivatives and methods of use
US6878714B2 (en) *	2001-01-12	2005-04-12	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US7105682B2 (en) *	2001-01-12	2006-09-12	Amgen Inc.	Substituted amine derivatives and methods of use
DE50204789D1 (de)	2001-05-10	2005-12-08	Solvay Pharm Gmbh	Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US6977264B2 (en) *	2001-07-25	2005-12-20	Amgen Inc.	Substituted piperidines and methods of use
GB0129015D0 (en) *	2001-12-04	2002-01-23	Glaxo Group Ltd	Compounds
GB0129013D0 (en) *	2001-12-04	2002-01-23	Glaxo Group Ltd	Compounds
SE0203302D0 (sv) *	2002-11-07	2002-11-07	Astrazeneca Ab	Novel Compounds
US7223788B2 (en) *	2003-02-14	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US7338954B2 (en)	2003-09-17	2008-03-04	Bristol-Myers Squibb Company	Compounds useful as motilin agonists and method
US7262195B2 (en)	2003-09-17	2007-08-28	Bristol-Myers Squibb Company	Compounds useful as motilin agonists and method
RU2006110272A (ru) *	2003-10-01	2007-11-10	Дзе Проктер Энд Гэмбл Компани (US)	Антагонисты гормона, концентрирующего меланин
JPWO2005063720A1 (ja) *	2003-12-25	2007-07-19	日本新薬株式会社	アミド誘導体及び医薬
WO2005077368A2 (fr)	2004-02-03	2005-08-25	Astrazeneca Ab	Nouveau traitement du reflux gastro-oesophagien pathologique iii
WO2005077345A1 (fr)	2004-02-03	2005-08-25	Astrazeneca Ab	Composes pour le traitement de la maladie du reflux gastro-oesophagien
WO2005077373A2 (fr)	2004-02-03	2005-08-25	Astrazeneca Ab	Nouveau traitement du reflux gastro-oesophagien pathologique ii
US20070293539A1 (en) *	2004-03-18	2007-12-20	Lansbury Peter T	Methods for the treatment of synucleinopathies
WO2005089502A2 (fr) *	2004-03-18	2005-09-29	The Brigham And Women's Hospital, Inc.	Traitement des synucleinopathies
SE0401345D0 (sv)	2004-05-25	2004-05-25	Astrazeneca Ab	Therapeutic compounds: Pyridine as scaffold
GB0611907D0 (en)	2006-06-15	2006-07-26	Glaxo Group Ltd	Compounds
WO2007007018A1 (fr)	2005-07-12	2007-01-18	Glaxo Group Limited	Derivés d’hétéroaryle pipérazine en tant qu’agonistes gpr38
PE20070180A1 (es) *	2005-07-26	2007-04-25	Glaxo Group Ltd	Compuestos de bencilpiperazina como agonistas del receptor gpr38
AU2007263712B2 (en) *	2006-06-28	2012-08-30	Glaxo Group Limited	Piperazinyl derivatives useful in the treatment of GPR38 receptor mediated diseases

2007
- 2007-06-26 AU AU2007263712A patent/AU2007263712B2/en not_active Ceased
- 2007-06-26 DK DK07765616.3T patent/DK2041093T3/da active
- 2007-06-26 SI SI200730257T patent/SI2041093T1/sl unknown
- 2007-06-26 HR HR20100284T patent/HRP20100284T1/hr unknown
- 2007-06-26 DE DE602007006019T patent/DE602007006019D1/de active Active
- 2007-06-26 JP JP2009517160A patent/JP5028484B2/ja not_active Expired - Fee Related
- 2007-06-26 PL PL07765616T patent/PL2041093T3/pl unknown
- 2007-06-26 NZ NZ573450A patent/NZ573450A/en not_active IP Right Cessation
- 2007-06-26 AR ARP070102835A patent/AR061656A1/es not_active Application Discontinuation
- 2007-06-26 EA EA200970065A patent/EA015820B1/ru not_active IP Right Cessation
- 2007-06-26 CA CA002655540A patent/CA2655540A1/fr not_active Abandoned
- 2007-06-26 WO PCT/EP2007/056342 patent/WO2008000729A1/fr not_active Ceased
- 2007-06-26 KR KR1020087031612A patent/KR20090031688A/ko not_active Ceased
- 2007-06-26 MX MX2009000110A patent/MX2009000110A/es active IP Right Grant
- 2007-06-26 BR BRPI0713443-6A patent/BRPI0713443A2/pt not_active IP Right Cessation
- 2007-06-26 ES ES07765616T patent/ES2344484T3/es active Active
- 2007-06-26 PE PE2007000819A patent/PE20080345A1/es not_active Application Discontinuation
- 2007-06-26 EP EP07765616A patent/EP2041093B1/fr active Active
- 2007-06-26 AT AT07765616T patent/ATE465150T1/de active
- 2007-06-26 US US11/768,339 patent/US7700599B2/en not_active Expired - Fee Related
- 2007-06-26 PT PT07765616T patent/PT2041093E/pt unknown
- 2007-06-26 TW TW096122969A patent/TWI391386B/zh not_active IP Right Cessation
- 2007-06-26 JO JO2007261A patent/JO2645B1/en active
2008
- 2008-12-11 IL IL195900A patent/IL195900A0/en unknown
- 2008-12-11 CR CR10497A patent/CR10497A/es not_active Application Discontinuation
- 2008-12-24 MY MYPI20085319A patent/MY147677A/en unknown
- 2008-12-30 MA MA31526A patent/MA30539B1/fr unknown
2009
- 2009-01-16 NO NO20090266A patent/NO20090266L/no not_active Application Discontinuation
- 2009-04-02 US US12/417,176 patent/US8853218B2/en not_active Expired - Fee Related
2010
- 2010-06-11 CY CY20101100521T patent/CY1110190T1/el unknown

Also Published As

Publication number	Publication date
US20080027065A1 (en)	2008-01-31
DK2041093T3 (da)	2010-08-02
TWI391386B (zh)	2013-04-01
EP2041093B1 (fr)	2010-04-21
AR061656A1 (es)	2008-09-10
AU2007263712B2 (en)	2012-08-30
HK1127608A1 (en)	2009-10-02
MA30539B1 (fr)	2009-06-01
WO2008000729A1 (fr)	2008-01-03
PL2041093T3 (pl)	2010-09-30
SI2041093T1 (sl)	2010-07-30
MX2009000110A (es)	2009-01-23
AU2007263712A1 (en)	2008-01-03
PE20080345A1 (es)	2008-05-29
TW200817352A (en)	2008-04-16
ES2344484T3 (es)	2010-08-27
ATE465150T1 (de)	2010-05-15
BRPI0713443A2 (pt)	2012-03-06
EP2041093A1 (fr)	2009-04-01
PT2041093E (pt)	2010-06-28
NZ573450A (en)	2011-11-25
JP2009541432A (ja)	2009-11-26
EA015820B1 (ru)	2011-12-30
JP5028484B2 (ja)	2012-09-19
CY1110190T1 (el)	2015-01-14
MY147677A (en)	2012-12-31
CR10497A (es)	2009-03-20
JO2645B1 (en)	2012-06-17
HRP20100284T1 (hr)	2010-06-30
KR20090031688A (ko)	2009-03-27
US7700599B2 (en)	2010-04-20
CA2655540A1 (fr)	2008-01-03
EA200970065A1 (ru)	2009-06-30
US20090192160A1 (en)	2009-07-30
IL195900A0 (en)	2009-09-01
US8853218B2 (en)	2014-10-07
DE602007006019D1 (de)	2010-06-02

Publication	Publication Date	Title
NO20090266L (no)	2009-03-17	Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
NO20070487L (no)	2007-03-05	3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20081212L (no)	2008-05-06	Xantinderivater som selektive HM74A agonister
NO20083905L (no)	2008-09-12	Nye pyron-indol derivater og fremgangsmate for deres fremstilling
NO20071246L (no)	2007-05-24	Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20081729L (no)	2008-05-16	Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20082124L (no)	2008-06-20	Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
NO20066081L (no)	2007-02-20	Kinazolinderivater som erbB-reseptortyrosinkinaser
NO20090628L (no)	2009-04-21	Pyridizinon derivativater
NO20073876L (no)	2007-09-10	Pyrazolopyrimidinderivater som mGluR2-antagonister
NO20063599L (no)	2006-10-27	Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20090267L (no)	2009-03-09	Substituerte N-fenylmetyl-5-okso-prolin-2-amider som P2X7-receptorantagonister og deres anvendelse
NO20080675L (no)	2008-03-13	P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20092342L (no)	2009-07-02	Azaspiroderivativater
NO20070489L (no)	2007-03-07	3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20070224L (no)	2007-04-02	2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20074258L (no)	2007-11-27	Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20084747L (no)	2008-11-25	Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
NO20084489L (no)	2008-12-19	Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
ATE542795T1 (de)	2012-02-15	Benzylpiperazinderivate als motilin- rezeptorantagonisten
NO20082709L (no)	2008-08-13	Kjemiske forbindelser
NO20081844L (no)	2008-05-29	Terapeutiske forbindelser
NO20082496L (no)	2008-07-24	Pyrazinderivater
GEP20084452B (en)	2008-08-10	Sulfonamide derivatives for the treatment of diseases
NO20081014L (no)	2008-04-10	Sammensetninger

Legal Events

Date	Code	Title	Description
2015-01-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application